A Global Pharmaceutical Company Partners with Bolloré Logistics Singapore for its First Asia Cross-Dock Healthcare Hub
A global pharmaceutical company, together with Bolloré Logistics Singapore, inaugurated their new Asian cross-dock hub on November 9, 2018.
The opening ceremony, which was graced by the management leaders of both companies, marked the official collaboration and partnership between the two global enterprises.
Based in the USA, the pharmaceutical company is one of the leading figures in biopharma industry with an extremely strong focus on treatments for diabetes and oncology. The opening of an Asian cross-dock hub would bring along a new distribution plan which plays a central role in the logistics management of products from the pharmaceutical plants in USA and Europe to the countries of its Asian markets. Under the new supply chain model, the logistic flows from origins to destinations will be fully handled and monitored by the international network of Bolloré Logistics.
With a fully GDP1 and GMP2-compliant healthcare warehouse located in the FTZ3, Bolloré Logistics provided a solution that is capable of fast turnaround while ensuring the products are stored in their optimal storage temperature environment – a criteria that is extremely critical for pharmaceutical cold chain management. The switch from air to ocean solution aims to bring along better supply chain security, cost savings, end-to-end visibility, and lower carbon footprint.
“This project would not be possible without the meticulous planning and involvement of the teams from both companies. With the first shipment already in motion, we are extremely proud to announce that the cross dock hub is officially in operations,” said Mr Remi Lefevre, General Sales Manager at Bolloré Logistics Singapore.
The project is a significant milestone for the two companies. The partnership will see both enterprises integrate innovative ideas to bring about a much more effective supply chain management for Healthcare logistics.
1. Good Distribution Practice (GDP) is that part of quality assurance which ensures products are consistently stored, transported and handled under suitable conditions as required by the marketing authorisation (MA) or product specification.
2. Good manufacturing practices (GMP) are the practices required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices.
3. Free Trade Zone